FDA told Biopreventative its website claim that compounded tadalafil is "commonly known as Cialis" misbrands the drug.
What happened
FDA reviewed the company's website, biopreventative.com, in August 2025 and found it offers compounded drug products including tadalafil. The site states: "Tadalafil (commonly known as Cialis) is a compound medication." FDA says that claim implies the compounded product is the same as the FDA-approved drug, which it is not, making the product misbranded.
What FDA found
The website describes compounded tadalafil in a way that suggests it is the same as the FDA-approved drug Cialis, when compounded drugs are not FDA-approved.
Section 502(a) FDCA [21 U.S.C. § 352(a)]Advertising or promoting a compounded drug in a false or misleading way makes that drug misbranded.
Section 502(bb) FDCA [21 U.S.C. § 352(bb)]Selling or shipping these misbranded drugs across state lines is a prohibited act.
Section 301(a) FDCA [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
Section 301(c) FDCA [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to stop using the misleading language immediately and, within 15 working days of receiving the letter, send a written response to the Office of Compounding Quality and Compliance describing the steps taken and how repeat violations will be prevented.
Who should pay attention
- telehealth sites and online sellers of compounded drugs
- compounding pharmacies that market products on their websites
- marketing and regulatory reviewers of drug product web content
This is a summary. Read the original letter on fda.gov.